{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MEHTSOP057 Sponsor Oversight 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT SPONSOR OVERSIGHT"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP057"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "th12 December 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th11 December 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins, R & D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "02/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn R & D Director, Clinical Lead Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: December 2019"
                    },
                    {
                        "text": "Distributio n Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "MEHTSOP057 Sponsor Oversight 1.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 13,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Hazel Guth"
                    },
                    {
                        "text": "Primary Care Research Nurse"
                    },
                    {
                        "text": "02/07/2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "MEHTSOP003 SAEs (Sponsored) MEHTSOP062 Trial Master File (Sponsored) SOP-07- Role of CI, pharmacy, nuclear medicine and R&D MEHTSOP043 Serious Breaches (Sponsored) MEHTSOP041 Risk Assessment Process"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "prefix": 15.0,
                "text": "Page  of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Applicable"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "text": "Appendix 1 - Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "text": "Appendix 2 - Requirements for the management and oversight of MEHT sponsored CTIMPS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "text": "Appendix 3 \u2013 Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 1,
                "prefix": 1.1,
                "text": "This document describes the procedures for the management and organisational oversight of Mid Essex Hospital Services NHS Trust (MEHT) sponsored clinical trials."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "The sponsor shall ensure that the relevant trial oversight committees (Trial Management Group, Trial Steering Committee, Dose Escalation Group, Data Monitoring Committee and Independent Data Monitoring Committee where applicable) are employed to ensure that the rights, safety and wellbeing of the trial participants are protected and to ensure that the trial is conducted, recorded and reported in accordance with the currently approved protocol and any amendments, SOPs, GCP and with the applicable clinical trial regulations."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "text": "\u25cf To specify which local management and organisational oversight groups should be in place for both single centre and multicentre MEHT Sponsored research studies."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "text": "\u25cf To outline the roles of the sponsor, Clinical Trial Statistician, R&D Department and Chief Investigator (or Designated Individual) in the management and organisational oversight for single centre and multicentre CTIMPs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "text": "\u25cf To outline the procedures for implementation and management of the respective oversight committee structures established for single and multicentre trials (appendix 2)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Any Trust employee (including those with an honorary research contract or letter of access) involved with clinical research sponsored by MEHT including, Chief Investigators (CI), Principal Investigators (PI), Consultants, Co-investigators, Clinical Trial Pharmacists, Research Managers, Statisticians, Research nurses, Research midwives, Allied Health Professionals, Trial Coordinators, R&D Department& Data Managers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "RESPONSIBILITIES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "The  Sponsor  shall ensure that there is a standard set of requirements for the management and oversight of both single centre and multicentre clinical trials that ensures appropriate levels of both local management and organisational oversight. This will complement the continual programme of clinical trials monitoring and audit conducted by the R&D office and existing systems for reporting on trial progress to R&D."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 1,
                "prefix": 4.2,
                "text": "The Research & Development department shall ensure that all MEHT sponsored clinical trials:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "text": "a) Have an appropriate level of management and organisational oversight."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "text": "b) Have an appropriate membership composition for trials requiring the formation of a DMC/IDMC (see appendix 2)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "text": "c) Are monitored to assess the progress of CTIMP trials by reviewing all reports/ recommendations produced by the DMC/IDMC and trial steering committee."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 1,
                "prefix": 4.3,
                "text": "The Clinical Study Statistician will ensure that the following responsibilities are carried out:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "text": "a) Shall create the first draft of the DMC/IDMC charter, which will then reviewed by all members of the DMC/IDMC and CI (or DI) before being finalised."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "text": "b) Shall make any amendments to the DMC/IDMC charter as required during the study."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "text": "c) Shall liaise with the trial coordinator/data manager to ensure they are notified of any information on the Serious Adverse Events that may have occurred on the trial up to that point. This should take place at least four weeks before a DMC/IDMC meeting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "text": "d) Shall ensure that the data in the trial database is analysed and commence writing the report to the DMC/IDMC at least two weeks before the meeting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "text": "e) Shall produce the DMC/IDMC report and distribute it to members of the DMC/IDMC at least 1 week before the meeting. This is to ensure that there is a sufficient interim period for the members to review the report and consider whether they require a study statistician and/or CI (or DI) to be present at the meeting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "text": "f) Shall ensure they are available, to attend the DMC/IDMC meeting and guide the committee through the report if required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 1,
                "prefix": 4.4,
                "text": "The R&D Department shall ensure that all the following responsibilities are carried out:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "text": "a) Shall review the oversight requirements as part of the governance checks."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "text": "b) Shall maintain a log of activity of the oversight committee meetings and facilitate the review of the recommendations outlined by the respective oversight committee group."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "c) Shall facilitate provision of any feedback to the CI and/or designee following review of the recommendations outlined where required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "d) Shall attend TMG/research team meetings regularly to ensure governance issues are highlighted and complied with correctly. The R&D department will ensure that any potential serious breaches identified or discussed at these meetings are escalated to the where necessary."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 1,
                "prefix": 4.5,
                "text": "The Chief Investigator and/or Delegated Individual shall ensure the following responsibilities are carried out:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "a) Shall ensure that the required oversight committee structure is incorporated into the design of the study protocol at the time of initial submission to R&D for review (Appendix 2)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "b) Shall ensure that all persons involved in the trial including the Study Statistician, Trial Coordinators/Data Manager, Research Nurses, Allied Health Professionals and the R&D Department are made aware that a DMC/IDMC meeting has been organised."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 1,
                "text": "c) Shall review the status of the study database at least 4 weeks before a scheduled DMC/IDMC meeting, and ensure that any required  data locks have been completed at least 2 weeks prior to the DMC/IDMC meeting."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "text": "d) Shall ensure that the Study Statistician is made aware of any other relevant information for the DMC/IDMC report."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "e) Shall facilitate the R&D Departments attendance during research team meetings/Trial Management Group meetings (as required)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "f) Shall assist in facilitating the Organisational Oversight Committee's meetings in whatever ways are deemed necessary by R&D department."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "g) Shall abide by any recommendations that the DMC/IDMC, Trial Steering Committee or sponsor require."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 1,
                "prefix": 4.6,
                "text": "Where responsibility for investigational product(s) accountability at the trial site has been delegated to the Pharmacy Department, the Clinical Trials Pharmacist shall ensure the following responsibilities are carried out:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "a) Shall ensure all records of the investigational product's delivery, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product is maintained. These records should include dates, quantities, batch/serial numbers, expiration dates (if applicable), and the unique code numbers assigned to the investigational product and trial subjects."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "b) Shall ensure that the investigational product is stored as specified by the sponsor and in accordance with applicable regulatory requirement(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "c) Shall ensure that the investigational product is only used in accordance with the approved protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "PROCEDURE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "R&D co-director and manager will decide on the level of oversight required for each study using Appendix 2 as a guideline. Comments prepared by the R&D department for these meetings should also remark on necessary trial oversight."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "prefix": 5.2,
                "text": "R&D co-director and manager will state the oversight requirements for the study. R&D co-director and manager will define a timeframe within which the first DMC/IDMC meeting should have occurred and will identify that the recommendations outlined by the oversight committee must be reviewed by the R&D co-director and manager. The R&D co-director and manager will ensure that a formal invitation is made to staff who are to form part of the DMC/IDMC for the trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "prefix": 5.3,
                "text": "The DMC/IDMC should report their recommendations in a letter or report to the CI electronically. The sponsor representative should be copied into this email who will in turn ensure that the recommendations are reviewed by R&D co-director and manager (usually the original reviewer of the study) If there is any information in the recommendations that is thought not to be shared with the CI, then the recommendations should only be sent to the Study Statistician. In this case, the Study Statistician should also be advised what to report to the CI. These recommendations should be filed in the appropriate electronic folder along with the DMC/IDMC report by the Study Statistician."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "prefix": 5.4,
                "text": "The CI should ensure that recommendations raised by the DMC/IDMC are responded to and address the issues raised in the recommendations."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "prefix": 5.5,
                "text": "The R&D Department should ensure that records are maintained identifying the activity of study specific oversight committees. The R&D Department will attend research team meetings/scheduled TMG meetings (where required) to assist with the resolution of any governance issues that may occur."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "prefix": 5.6,
                "text": "A written acknowledgement will be issued following the review of the recommendations outlined by the DMC/IDMC to the CI by the R&D co-director and manager and will detail any additional recommendations made by the R&D co- director and manager to the CI. This written response should be maintained within the TMF by the CI."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to Appendix 3)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 1,
                "text": "Adverse Event (AE) -  Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator (CI) -  The person who takes overall responsibility for the design, conduct and reporting of a study if it is at one site; or if the study involves researchers at more than one site, the person who takes primary responsibility for the design conduct and reporting of the study whether or not that person is an Investigator at any particular site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial - Any investigation in human subjects intended to discover or verify the clinical, pharmacological and / or other pharmacodynamic effects of one or more investigational medicinal product(s), and/or to identify any adverse reactions to one or more investigational medicinal product(s) and / or to study absorption, distribution, metabolism and excretion of one or more investigational medicinal product(s) with the object of ascertaining its (their) safety and / or efficacy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial of an Investigational Medicinal Product (CTIMP) - This is defined as any Clinical Research Study which intends to generate new information about the safety or efficacy of a Medicinal Product."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 1,
                "text": "Data Lock Point - This should be the last day of the one year reporting period and the DSUR should be submitted to the MHRA and the REC no later than 60 days after the data lock date."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 1,
                "text": "Data Monitoring Committee (DMC): A group of experts (including Clinical experts, Statisticians and if appropriate Ethicists and Patient Advocates) not associated with the trial that monitor safety and efficacy data while a trial is ongoing. The role of the Data Monitoring Committee is to review the accruing trial data and to assess whether there are any safety issues that should be brought to participants attention or any reasons for the trial not to continue. The DMC may comprise of MEHT staff who are independent from the study, but specialists who are independent from MEHT can also be included. As a minimum, an Independent Chair, Statistician and Clinician to the study should be present during DMC meetings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 1,
                "text": "Delegated Individual (DI) - An individual delegated by the PI to carry out their task(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 1,
                "text": "Good Clinical Practice (GCP) - The principles of Good Clinical Practice in Clinical Trials as set down in Articles 2-5 of the GCP Directive and implemented in the UK by Schedule 1 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I.2004/1031) as amended by S.I. 2006/1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "Good Clinical Practice is a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 1,
                "text": "Honorary Research Contract (HRC) - HRCs are required for researchers who are not employees of the NHS and whose activities could have a foreseeable and direct impact on patient care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 1,
                "text": "Independent Data Monitoring Committee (IDMC) - A group of experts (including Clinical Experts, Statisticians and if appropriate Ethicists and Patient Advocates) not associated with the trial and all independent of MEHT that monitor safety and efficacy data while a trial is ongoing. The role of the Independent Data Monitoring Committee is to review the accruing trial data and to assess whether there are any safety issues that should be brought to participants attention or any reasons for the trial not to continue."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 1,
                "text": "International Conference on Harmonisation (ICH) -  International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use is a joint initiative involving both regulators and research-based industry focusing on the technical requirements for medicinal products containing new drugs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 1,
                "text": "Investigational Medicinal Products (IMP) -  A pharmaceutical form of an active substance or placebo being tested, or used as a reference in a clinical trial. This includes a medicinal product which has a marketing authorisation but is, for the purposes of the trial -"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "text": "(a) used or assembled (formulated or packaged) in a way different from the form of the product authorised under the authorisation,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "text": "(b) used for an indication not included in the summary of product characteristics under the authorisation for that product, or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "(c) used to gain further information about the form of that product as authorised under the authorisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 1,
                "text": "Letter of Access - Letters of access enable NHS employees or staff with an honorary clinical contract (e.g. clinical academics) with one NHS organisation to conduct research in another NHS organisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 1,
                "text": "Principal Investigator (PI) - The leader responsible for a team of individuals conducting a study at a (participating) site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 1,
                "text": "Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) - Any untoward medical occurrence or effect that at any dose results in:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Death"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is life-threatening*"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Requires hospitalisation or prolongation of existing hospitalisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Results in persistent or significant disability or incapacity"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is a congenital anomaly or birth defect"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is an important medical event"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "* \u201clife-threatening\u201d refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 1,
                "prefix": 1928.0,
                "text": "The Regulations -  Medicines for Human Use (Clinical Trial) Regulations 2004 transposed the EU Clinical Trials Directive into UK legislation, as Statutory Instrument 2004 no  This became effective on the 1st May  An amendment to implement Directive 2005/28/EC was made to the Regulations as Statutory Instrument 2006 no"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 1,
                "text": "Trial Management Group (TMG) - The Trial Management Group for each trial is set up to oversee the clinical and practical aspects of the day to day management of the trial. The TMG normally includes individuals such as the Chief Investigator, Trial Physician(s), Statistician, Trial Coordinator, Research Nurse, and Data Manager(s). The role of the group is to monitor all aspects of the conduct and progress of the trial, ensure that the protocol is adhered to and take appropriate action to safeguard participants and the quality of the trial itself."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 1,
                "text": "Trial Master File - The Trial Master File (TMF) will be held at the principal site by the sponsor, Chief Investigator or at the co-ordinating Centre. The TMF should contain all essential documents defined as documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. A Trial Master File should be set up at the beginning of a trial and maintained up-to-date throughout the trial until trial conclusion."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "text": "For trials currently running, it is recommended that Section 8 of the ICH-GCP Guideline is followed as guidance in order to meet statutory requirements. However, some of the documents listed may not be available or applicable in many non-commercial trials. The appropriate documentation will vary according to the trial and sponsor requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 1,
                "text": "Trial Steering Committee (TSC) - The role of the Trial Steering Committee is to provide overall supervision and monitoring of the trial towards its interim and overall objectives and to oversee adherence to the protocol and patient safety. The Trial Steering Committee should accept the approved trial protocol and agree on subsequent amendments to the study protocol before they are submitted to the sponsor. In addition the TSC should provide advice to the investigators on all aspects to the trial. A Trial Steering Committee should have members who are independent of the investigators (i.e. independent to the study). Decisions about continuation or termination of the trial or substantial amendments to the protocol are usually the responsibility of the Trial Steering Committee, taking into account reports/advice of the (I)DMC."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Requirements for the management and oversight of MEHT sponsored CTIMPS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 1,
                "text": "Single Centre Clinical Trials (50 patients' maximum)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "Single centre clinical trials must be managed by a local Trial Management Group (TMG). The Trial Management Group must include individuals who are responsible for the day to day management of the trial for example the CI, Trial Coordinator, Statistician, Research Nurse and Data Manager. This would usually be part of the research team meeting, where all staff involved in the trial contributes to discussion around trial progress, in particular reviewing adverse events. The frequency of TMG meetings is not mandated but is likely to be greater initially (2-3 times per year) ensuring that a minimum of 1 meeting is held annually. The frequency may reduce once the trial is in follow up (once a year or as required)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "The frequency of meetings should be stated in the trial protocol or monitoring plan which will be approved by the R&D co-director or R&D manager."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "text": "The CI/DI should ensure that minutes from all TMG meetings are maintained and where necessary issues which require escalation should be highlighted to the Sponsor. A copy of the minutes, approved by the CI or DI should be retained within the Trial Master File. Email approval of any documentation, including the minutes is considered sufficient. The Clinical Trial Coordinators/Data Managers should monitor the action points and ensure members understand and undertake actions agreed at this meeting. Where necessary issues identified which require escalation to the Sponsor should be communicated to the R&D Department."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "Single centre trials will be subject to external audit and monitoring by the R&D Department."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 1,
                "text": "Single Centre Clinical Trials (In excess of 50 patients)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 1,
                "text": "For Single Centre Trials with a recruitment target in excess of 50 patients a TMG must be set up as detailed above. In addition a Data Monitoring Committee should be established. The DMC may be comprised of MEHT staff and as a minimum should comprise a Chair, Trial Statistician and a further Clinician. Alternatively DMC members maybe from other institutions. The CI will be invited to suggest suitable candidates for the DMC, and it may be appropriate for a DMC to take responsibility for a number of clinical trials in similar areas of investigation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "text": "The role of the DMC should be to safeguard the interests of the trial participants, monitor the main outcome measures, including safety and efficacy, and monitor the overall conduct of the trial. The DMC should meet at least annually. For high risk studies additional meetings of the DMC should be convened at the discretion of the sponsor and/or the DMC."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "text": "Single Centre Trials will be subject to external audit and monitoring by the R&D Department."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 1,
                "text": "Multi Centre Trials (Maximum 3 centres)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 0,
                "text": "For such studies a Trial management group must be established and should include representation from all of the participating centres. The frequency of TMG meetings should occur at least every 3 months and may occur more frequently for high risk studies."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "text": "A Data Monitoring Committee must also be established. The membership of which will be formally agreed by the R&D co-director or R&D manager. The DMC may be comprised of MEHT staff and as a minimum should comprise a Chair, Trial Statistician and a further Clinician. Alternatively DMC members maybe from other institutions."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "text": "The CI will be invited to suggest suitable candidates for the DMC, and it may be appropriate for a DMC to take responsibility for a number of clinical trials in similar areas of investigation. The DMC meeting should convene at least annually but can be convened more frequently at the discretion of the sponsor and/or DMC."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "text": "Evidence of systems for monitoring the conduct of trial activity at participating sites is required prior to local approval and should include both systems for central monitoring of participating sites and arrangements for onsite monitoring as may be required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 0,
                "text": "Each group should have a defined constitution with terms of reference and a formal schedule of meeting dates. In order to ensure DMC meetings carry out their full purpose for the clinical trials, a charter should be produced by the clinical trial statistician to provide a clear structure for these meetings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 1,
                "text": "Trials Exceeding 3 Centres"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "text": "In order for MEHT to accept sponsorship of larger multi centre trials, the research team would be required to formally establish:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 1,
                "text": "Evidence of systems for monitoring the conduct of trial activity at participating sites is required prior to local approval and should include both systems for remote monitoring and arrangements for on-site source data verification."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "text": "Multi Centre Trials will be subject to external audit and monitoring with monitoring from the R&D Department."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "text": "Each group should have a defined constitution with terms of reference and a formal schedule of meeting dates. In order to ensure IDMC meetings carry out their full purpose for the clinical trials, a charter should be produced by the clinical trial statistician to provide a clear structure for these meetings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "text": "Both the IDMC and the TSC should be established in accordance with MRC Guidelines."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Sponsor Oversight / MEHTSOP057/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research & Development Sponsor Oversight / MEHTSOP057"
            }
        },
        {
            "type": "table",
            "sequence_num": 125,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "New SOP"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Review"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 127,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Sponsor Oversight / MEHTSOP057/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        }
    ]
}